Abstract
To assess the antitumor efficacy and safety profile of the combination of Fluorouracil (5FU) and vinorelbine given as first-line therapy to patients with advanced breast cancer. As defined in the seven consecutive steps of a phase II group sequential design, 63 patients received 5FU 750 mg/m2/d for 5 consecutive days as a continuous infusion and vinorelbine 30 mg/ m2 on days 1 and 5 as a short intravenous (I/V) infusion every 3 weeks. Forty-one of 63 patients achieved an objective response, which allowed us to discontinue the study and reject a response rate less than 50% with a statistical power of 90%. The unbiased estimate of the response rate was 61.6%. Response rate did not differ significantly according to the following: (1) type of prior adjuvant therapy (none, n = 23; without anthracycline, n = 6; with anthracyline, n = 34); (2) site of metastatic disease; and (3) number of metastatic sites. The median time to progression was 8.4 months. The median response duration was 12.3 months, and the median duration of complete response (CR), from the first assessment of CR, was 7.3 months. The median overall survival time was 23 months (28.1 months for patients with a CR). The main toxicities (grades 3 and 4) were neutropenia (9...Continue Reading
Citations
Oct 4, 2000·Breast Cancer Research and Treatment·M ZambettiF Garbagnati
Jun 26, 2001·The Oncologist·H S HochsterR White
Nov 27, 2001·British Journal of Cancer·P H CottuM Marty
Sep 24, 2005·Fundamental & Clinical Pharmacology·Véronique Sébille, Eric Bellissant
Dec 24, 2005·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·José Luis González VelaJuan Francisco González Guerrero
Jun 24, 2006·The Oncologist·Alexandros ArdavanisGerassimas Rigatos
Aug 25, 2007·Cancer Chemotherapy and Pharmacology·Marwan GhosnUNKNOWN Cancer Research Group/Collaborative Group (CRG/CG), Beirut-Lebanon
Oct 22, 2008·Expert Opinion on Pharmacotherapy·Jacques Bonneterre, Nicolas Penel
Aug 13, 2009·Journal of Cancer Research and Clinical Oncology·George OrphanosGerassimos Rigatos
Oct 3, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A BerrutiL Dogliotti
Apr 19, 2002·Chronobiology International·B Coudert
Mar 17, 2005·British Journal of Cancer·K H YehA L Cheng
Feb 5, 2011·Chemotherapy·Weidong MaoShangang Wu
Apr 18, 2001·The Oncologist·F J EstevaG N Hortobagyi
Mar 8, 2006·Anti-cancer Drugs·Thierry PetitEsteban Cvitkovic
Sep 10, 2008·Chronobiology International·Bruno CoudertFrancis Lévi
Apr 9, 2004·Cancer Investigation·Evangelia RazisGeorge Fountzilas
Nov 20, 2002·British Journal of Cancer·J BonneterreS Assadourian
Aug 17, 2004·Journal of Korean Medical Science·Jin-Hee AhnWoo Kun Kim
Apr 13, 1999·American Journal of Clinical Oncology·F TurpinF Biville
Aug 31, 2000·Breast Cancer Research and Treatment·A ZambelliG Robustelli della Cuna
Nov 25, 2017·The Hastings Center Report·Laura E Bothwell, Aaron S Kesselheim
Dec 2, 2020·Acta Oncologica·Anne Sofie Brems-EskildsenSven Tyge Langkjer
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L ZelekM Spielmann
Dec 12, 2001·Critical Reviews in Oncology/hematology·M S AaproJ B Vermorken
Nov 24, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F NolèA Goldhirsch